8New Articles on Hepatitis C

[Guest guest]

News

8 new results for Hepatitis

Vertex treatment meets safety goal in study

BusinessWeek

Vertex Pharmaceuticals Inc. said Thursday that a potential hepatitis C treatment

was safe and tolerable in a midstage study. The study involved a combination of

telaprevir and VX-222 with pegylated-interferon and ribavirin and focused on

people with ...

See all stories on this topic »

EASL: Telaprevir Helps in Prior HCV Tx Failures

MedPage Today

Explain that in this study, adding telaprevir to peginterferon alfa-2a plus

ribavirin significantly increased sustained response rates for patients with

genotype 1 hepatitis C virus infection who had previously failed the standard

regimen. ...

See all stories on this topic »

First Vaccine for Viral Hepatitis C Could Become a Reality

PR Newswire (press release)

Professor Heiner Wedemeyer, EASL's Secretary General commented: “Vaccines are an

exciting area of research now with the potential to add to the range of

treatments available for patients with chronic viral hepatitis. These are early

data but results ...

See all stories on this topic »

Sustained viral response achieved in 83% of hepatitis C infected patients with

....

Montreal Gazette

Preclinical characterization of the hepatitis C virus NS5B polymerase

non-nucleoside inhibitor BILB 1941 (Poster 1215. G. Kukolj et. al.) Posters are

presented on Saturday, 2 April, 2011, 09:00h - 18:00h. HCV is an infectious

disease of the liver and ...

See all stories on this topic »

Biolex Announces Hepatitis Trial Data

Drug Discovery & Development

Biolex Therapeutics, Inc. announced that final 72-week results from its SELECT-2

Phase 2b trial of Locteron for the treatment of hepatitis C were presented at

the 46th Annual Meeting of the European Association for the Study of the Liver

(EASL) in ...

See all stories on this topic »

Did WWE HOFer Abdullah the Butcher give a fellow wrestler Hepatitis C?

Cageside Seats (blog)

He claims that his lawyer has asked Shreve to provide him with paperwork proving

that he doesn't have Hepatitis C, but they haven't received any response. In the

documentary, Abdullah's habit of cutting people (wrestlers or otherwise) without

their ...

See all stories on this topic »

Novartis first-in-class antiviral DEB025 achieved sustained viral response in

....

IEWY News

Basel, – Novartis announced today that a Phase II study with the first-in-class

antiviral DEB025 (alisporivir) met its primary endpoint for achieving viral cure

(24 weeks after stopping treatment) in 76% of patients with chronic hepatitis

C[1]. ...

See all stories on this topic »

April marks national STD awareness month

KTKA.com

Vaccines are available to help protect against the two most common sexually

transmitted infections, Hepatitis B and Human Papillomavirus (HPV). Both

vaccinations can be obtained through SCHA's immunization department during

regular business hours. ...

See all stories on this topic »

Tip: Use a minus sign (-) in front of terms in your query that you want to

exclude. Learn more.

[Guest guest]

News

8 new results for Hepatitis

Vertex treatment meets safety goal in study

BusinessWeek

Vertex Pharmaceuticals Inc. said Thursday that a potential hepatitis C treatment

was safe and tolerable in a midstage study. The study involved a combination of

telaprevir and VX-222 with pegylated-interferon and ribavirin and focused on

people with ...

See all stories on this topic »

EASL: Telaprevir Helps in Prior HCV Tx Failures

MedPage Today

Explain that in this study, adding telaprevir to peginterferon alfa-2a plus

ribavirin significantly increased sustained response rates for patients with

genotype 1 hepatitis C virus infection who had previously failed the standard

regimen. ...

See all stories on this topic »

First Vaccine for Viral Hepatitis C Could Become a Reality

PR Newswire (press release)

Professor Heiner Wedemeyer, EASL's Secretary General commented: “Vaccines are an

exciting area of research now with the potential to add to the range of

treatments available for patients with chronic viral hepatitis. These are early

data but results ...

See all stories on this topic »

Sustained viral response achieved in 83% of hepatitis C infected patients with

....

Montreal Gazette

Preclinical characterization of the hepatitis C virus NS5B polymerase

non-nucleoside inhibitor BILB 1941 (Poster 1215. G. Kukolj et. al.) Posters are

presented on Saturday, 2 April, 2011, 09:00h - 18:00h. HCV is an infectious

disease of the liver and ...

See all stories on this topic »

Biolex Announces Hepatitis Trial Data

Drug Discovery & Development

Biolex Therapeutics, Inc. announced that final 72-week results from its SELECT-2

Phase 2b trial of Locteron for the treatment of hepatitis C were presented at

the 46th Annual Meeting of the European Association for the Study of the Liver

(EASL) in ...

See all stories on this topic »

Did WWE HOFer Abdullah the Butcher give a fellow wrestler Hepatitis C?

Cageside Seats (blog)

He claims that his lawyer has asked Shreve to provide him with paperwork proving

that he doesn't have Hepatitis C, but they haven't received any response. In the

documentary, Abdullah's habit of cutting people (wrestlers or otherwise) without

their ...

See all stories on this topic »

Novartis first-in-class antiviral DEB025 achieved sustained viral response in

....

IEWY News

Basel, – Novartis announced today that a Phase II study with the first-in-class

antiviral DEB025 (alisporivir) met its primary endpoint for achieving viral cure

(24 weeks after stopping treatment) in 76% of patients with chronic hepatitis

C[1]. ...

See all stories on this topic »

April marks national STD awareness month

KTKA.com

Vaccines are available to help protect against the two most common sexually

transmitted infections, Hepatitis B and Human Papillomavirus (HPV). Both

vaccinations can be obtained through SCHA's immunization department during

regular business hours. ...

See all stories on this topic »

Tip: Use a minus sign (-) in front of terms in your query that you want to

exclude. Learn more.

[Guest guest]

News

8 new results for Hepatitis

Vertex treatment meets safety goal in study

BusinessWeek

Vertex Pharmaceuticals Inc. said Thursday that a potential hepatitis C treatment

was safe and tolerable in a midstage study. The study involved a combination of

telaprevir and VX-222 with pegylated-interferon and ribavirin and focused on

people with ...

See all stories on this topic »

EASL: Telaprevir Helps in Prior HCV Tx Failures

MedPage Today

Explain that in this study, adding telaprevir to peginterferon alfa-2a plus

ribavirin significantly increased sustained response rates for patients with

genotype 1 hepatitis C virus infection who had previously failed the standard

regimen. ...

See all stories on this topic »

First Vaccine for Viral Hepatitis C Could Become a Reality

PR Newswire (press release)

Professor Heiner Wedemeyer, EASL's Secretary General commented: “Vaccines are an

exciting area of research now with the potential to add to the range of

treatments available for patients with chronic viral hepatitis. These are early

data but results ...

See all stories on this topic »

Sustained viral response achieved in 83% of hepatitis C infected patients with

....

Montreal Gazette

Preclinical characterization of the hepatitis C virus NS5B polymerase

non-nucleoside inhibitor BILB 1941 (Poster 1215. G. Kukolj et. al.) Posters are

presented on Saturday, 2 April, 2011, 09:00h - 18:00h. HCV is an infectious

disease of the liver and ...

See all stories on this topic »

Biolex Announces Hepatitis Trial Data

Drug Discovery & Development

Biolex Therapeutics, Inc. announced that final 72-week results from its SELECT-2

Phase 2b trial of Locteron for the treatment of hepatitis C were presented at

the 46th Annual Meeting of the European Association for the Study of the Liver

(EASL) in ...

See all stories on this topic »

Did WWE HOFer Abdullah the Butcher give a fellow wrestler Hepatitis C?

Cageside Seats (blog)

He claims that his lawyer has asked Shreve to provide him with paperwork proving

that he doesn't have Hepatitis C, but they haven't received any response. In the

documentary, Abdullah's habit of cutting people (wrestlers or otherwise) without

their ...

See all stories on this topic »

Novartis first-in-class antiviral DEB025 achieved sustained viral response in

....

IEWY News

Basel, – Novartis announced today that a Phase II study with the first-in-class

antiviral DEB025 (alisporivir) met its primary endpoint for achieving viral cure

(24 weeks after stopping treatment) in 76% of patients with chronic hepatitis

C[1]. ...

See all stories on this topic »

April marks national STD awareness month

KTKA.com

Vaccines are available to help protect against the two most common sexually

transmitted infections, Hepatitis B and Human Papillomavirus (HPV). Both

vaccinations can be obtained through SCHA's immunization department during

regular business hours. ...

See all stories on this topic »

Tip: Use a minus sign (-) in front of terms in your query that you want to

exclude. Learn more.

[Guest guest]

News

8 new results for Hepatitis

Vertex treatment meets safety goal in study

BusinessWeek

Vertex Pharmaceuticals Inc. said Thursday that a potential hepatitis C treatment

was safe and tolerable in a midstage study. The study involved a combination of

telaprevir and VX-222 with pegylated-interferon and ribavirin and focused on

people with ...

See all stories on this topic »

EASL: Telaprevir Helps in Prior HCV Tx Failures

MedPage Today

Explain that in this study, adding telaprevir to peginterferon alfa-2a plus

ribavirin significantly increased sustained response rates for patients with

genotype 1 hepatitis C virus infection who had previously failed the standard

regimen. ...

See all stories on this topic »

First Vaccine for Viral Hepatitis C Could Become a Reality

PR Newswire (press release)

Professor Heiner Wedemeyer, EASL's Secretary General commented: “Vaccines are an

exciting area of research now with the potential to add to the range of

treatments available for patients with chronic viral hepatitis. These are early

data but results ...

See all stories on this topic »

Sustained viral response achieved in 83% of hepatitis C infected patients with

....

Montreal Gazette

Preclinical characterization of the hepatitis C virus NS5B polymerase

non-nucleoside inhibitor BILB 1941 (Poster 1215. G. Kukolj et. al.) Posters are

presented on Saturday, 2 April, 2011, 09:00h - 18:00h. HCV is an infectious

disease of the liver and ...

See all stories on this topic »

Biolex Announces Hepatitis Trial Data

Drug Discovery & Development

Biolex Therapeutics, Inc. announced that final 72-week results from its SELECT-2

Phase 2b trial of Locteron for the treatment of hepatitis C were presented at

the 46th Annual Meeting of the European Association for the Study of the Liver

(EASL) in ...

See all stories on this topic »

Did WWE HOFer Abdullah the Butcher give a fellow wrestler Hepatitis C?

Cageside Seats (blog)

He claims that his lawyer has asked Shreve to provide him with paperwork proving

that he doesn't have Hepatitis C, but they haven't received any response. In the

documentary, Abdullah's habit of cutting people (wrestlers or otherwise) without

their ...

See all stories on this topic »

Novartis first-in-class antiviral DEB025 achieved sustained viral response in

....

IEWY News

Basel, – Novartis announced today that a Phase II study with the first-in-class

antiviral DEB025 (alisporivir) met its primary endpoint for achieving viral cure

(24 weeks after stopping treatment) in 76% of patients with chronic hepatitis

C[1]. ...

See all stories on this topic »

April marks national STD awareness month

KTKA.com

Vaccines are available to help protect against the two most common sexually

transmitted infections, Hepatitis B and Human Papillomavirus (HPV). Both

vaccinations can be obtained through SCHA's immunization department during

regular business hours. ...

See all stories on this topic »

Tip: Use a minus sign (-) in front of terms in your query that you want to

exclude. Learn more.